06.12.2020 • NewsBayer

US Judge Rejects Bayer’s PCB Settlement Plan

In yet another legal repercussion of Bayer’s 2018 acquisition of Monsanto, a US federal judge has rejected the German group’s proposed $648 million settlement of class-action litigation over historic contamination from polychlorinated biphenyls (PCBs).

The proposal was part of a $12 billion package announced in June this year, most of which covered litigation involving the US chemical group’s Roundup herbicide. In rejecting the PCB settlement, Fernando Olguin, district judge in Los Angeles, California, said it appeared “overly broad.”

Not only would the terms protect Bayer from future claims, Olguin said, they would also require the settling plaintiffs to indemnify the group against such claims. This, he noted, would affect most of the 2,528 class members. These included cities such as San Diego, California, Baltimore, Maryland, and Portland, Oregon, which stood to receive “very modest” payments of just $15,000 to $30,000. 

Olguin has given Bayer until the end of 2020 to adjust its proposal, a deadline the group has said it will meet.

Once widely used in applications ranging from equipment insulation to floor finish and paints and coatings, PCBs were banned by the US federal government in 1979 on suspicion that they could cause cancer and other health problems. Monsanto produced the chemicals from 1935 to 1977.

Author: Dede Williams, Freelance Journalist

A US federal judge has rejected Bayer’s proposed $648 million settlement of...
A US federal judge has rejected Bayer’s proposed $648 million settlement of class-action litigation over historic contamination from polychlorinated biphenyls. The judge has given Bayer until end 2020 to adjust its proposal, part of a $12 billion package announced in June. (c) Bayer

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.